MTOR and systemic lupus erythematosus: Blockade of mTOR with rapamycin, which is an effective treatment in patients with systemic lupus erythematosus [16], [17], inhibited the oxidative stress-induced expression of HRES-1/Rab4 and the lysosomal degradation of CD4 and CD3ζ [13].